Liquidia Technologies, Inc. (NASDAQ:LQDA) CFO Michael Kaseta Sells 11,580 Shares

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 11,580 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.28, for a total value of $165,362.40. Following the transaction, the chief financial officer directly owned 406,412 shares in the company, valued at approximately $5,803,563.36. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Liquidia Technologies Price Performance

Shares of NASDAQ:LQDA traded down $0.19 during trading on Friday, reaching $14.41. 929,859 shares of the company's stock traded hands, compared to its average volume of 1,301,902. The firm has a market cap of $1.23 billion, a PE ratio of -9.14 and a beta of -0.01. The company has a 50-day simple moving average of $14.88 and a 200-day simple moving average of $14.48. The company has a quick ratio of 2.91, a current ratio of 2.93 and a debt-to-equity ratio of 2.08. Liquidia Technologies, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $19.41.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. The business had revenue of $3.12 million for the quarter, compared to analysts' expectations of $3.23 million. As a group, analysts predict that Liquidia Technologies, Inc. will post -1.51 earnings per share for the current year.

Institutional Trading of Liquidia Technologies

Hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers lifted its holdings in shares of Liquidia Technologies by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after acquiring an additional 1,277 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Liquidia Technologies by 53.4% in the 4th quarter. Deutsche Bank AG now owns 51,075 shares of the company's stock worth $601,000 after acquiring an additional 17,790 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Liquidia Technologies in the 4th quarter worth approximately $218,000. Millennium Management LLC acquired a new position in shares of Liquidia Technologies in the 4th quarter worth approximately $526,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Liquidia Technologies by 9.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock worth $5,040,000 after acquiring an additional 38,313 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on LQDA shares. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer set a $13.00 target price on shares of Liquidia Technologies and gave the stock an "underperform" rating in a report on Monday, May 19th. Scotiabank raised their target price on shares of Liquidia Technologies from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a report on Wednesday, May 28th. HC Wainwright raised their target price on shares of Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, May 28th. Finally, Needham & Company LLC reissued a "buy" rating on shares of Liquidia Technologies in a report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Liquidia Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $26.89.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).